HIK Hikma Pharmaceuticals Plc

 

TIDMHIK 
 
RNS Number : 7281L 
Hikma Pharmaceuticals Plc 
15 January 2009 
 

 
 
Hikma Pharmaceuticals PLC - 
 
 
LONDON, 15 January 2009: Hikma Pharmaceuticals PLC ("the company") (LSE: HIK) 
(Nasdaq Dubai: HIK) announces that in accordance with the FSA announcement on 9 
January 2009 with respect to DTR 3.1.2, the following directors and Darhold 
Limited, a connected person, have pledged shares in the Company. 
 
 
Samih Darwazah, the Chairman, has pledged 2,195,450 shares as collateral for 
loans entered into on 17 December 2007, 24 April 2008 and 22 October 2008. 
 
 
Mazen Darwazah, an executive director, has pledged 400,000 shares as collateral 
for a loan entered into on 7 January 2009. 
 
 
Mr Ali Al-Husry, a non executive director, has pledged 1,000,000 shares as 
collateral for a loan entered into in June 2008. 
 
 
Darhold Limited, being a connected person of Samih Darwazah, Ali Al-Husry and 
Mazen Darwazah for the purposes of the Listing Rules, has pledged 37,800,000 
shares as collateral for loans entered into in March 2006, May 2007, January, 
February and April 2008. 
 
 
- ENDS - 
Enquiries: 
 
 
+--------------------------------+------------------------------------+ 
| Hikma Pharmaceuticals PLC      |                                    | 
+--------------------------------+------------------------------------+ 
| Henry Knowles                  | +44 20 7399 2760                   | 
| Company Secretary              |                                    | 
|                                |                                    | 
+--------------------------------+------------------------------------+ 
| Peter Laing                    | + 44 20 7399 2760                  | 
| Investor Relations             |                                    | 
+--------------------------------+------------------------------------+ 
Brunswick Group 
Jon Coles/ Justine McIlroy      + 44 20 7404 5959 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed pharmaceutical products.  Hikma's operations 
are conducted through three businesses: "Branded", "Injectables" and "Generics". 
 Hikma's operations are based principally in the Middle East and North Africa 
("MENA") region, where it is a market leader and sells across 17 countries, the 
United States and Europe.  In 2007, the Group achieved revenues of $449 million 
(2006 $317 million) and profit attributable to shareholders was $63 million 
(2006 $55 million).  For news and other information, please visit www.hikma.com. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSBUGDBUUBGGCU 
 

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024